Cytoreductive Surgery & HIPEC Scrubber
Cytoreductive surgery paired with hyperthermic intraperitoneal chemotherapy (HIPEC) demands rigorous multi-specialty surgical coordination across surgical oncology and gynecologic oncology. Yet commercial payers frequently reject heated chemoperfusion (+96560) as experimental, downcode extensive peritonectomies, and bundle concomitant bowel resections. Audit your complex surgical oncology claims with automated clinical rules.
Cytoreductive Surgery & HIPEC Perfusion Scrubber
Audit extensive multivisceral peritonectomy (49205), defend 90-minute hyperthermic chemoperfusion (+96560), safeguard concomitant bowel/splenic resections with Modifier -51, and coordinate Modifier -62 co-surgery.
1. Cytoreductive Surgery (CRS) Scope
2. Hyperthermic Chemoperfusion (HIPEC 96560)
3. Concomitant Segmental Colectomy / LAR (44140)
4. Concomitant En Bloc Splenectomy (38100)
5. Co-Surgeon Modifier -62 Alignment
6. Post-HIPEC ICU Surgical Critical Care (99291)
Clinical Audit Findings4 Rules Fired
Documentation confirms debulking of confluent peritoneal nodules >10.0 cm across multiple abdominal regions. Defends against downcoding to simple omentectomy.
Perfusion administration is defended with explicit telemetry: target temperatures, chemotherapeutic agent delivery, pump circulation rates, and physiologic monitoring.
Segmental bowel resection for oncologic tumor clearance is distinct from peritoneal implant stripping and payable with Modifier -51 under NCCI.
Modifier -24 allows reporting of intensive physiological resuscitation during the 90-day surgical global period when acute organ failure is documented.
Scrubbed Service Lines
Excision or destruction of peritoneal implants; largest tumor diameter >10 cm (multivisceral peritonectomy)
Multivisceral peritoneal stripping (diaphragm, pelvic peritoneum, mesentery) for peritoneal carcinomatosis. Modifier 62 split (62.5%).
Intraperitoneal chemotherapy administration, including monitoring (90-minute hyperthermic peritoneal chemoperfusion)
Clean HIPEC perfusion: Documented closed-circuit inflow/outflow catheter placement, target 41-43°C bath, mitomycin-C/cisplatin dosing, and 90-min dwell.
Colectomy, partial; with anastomosis (segmental bowel resection for tumor invasion)
Clean secondary visceral resection: Segmental colectomy for transmural tumor invasion with primary stapled anastomosis; Modifier -51 appended.
Splenectomy; total (en bloc splenic resection for splenic flexure/hilar peritoneal disease)
Clean visceral resection: En bloc splenectomy with ligation of splenic artery and vein at pancreatic tail.
Critical care, evaluation and management of the critically ill patient; first 30-74 minutes (post-HIPEC ICU resuscitation)
Clean critical care: Day 1 ICU management of massive third-spacing, coagulopathy, and vasopressor titration; Modifier -24 appended.
Turn these Surgical Oncology & Peritoneal Malignancy RCM insights into recovered cash
Frustrated by commercial payer denials on 90-minute HIPEC perfusion (+96560), downcoded peritonectomy claims, or unbundling rejections on concomitant visceral resections? Aethera's oncology surgical coding specialists ensure every dollar earned is recovered. Let our senior AAPC-certified billing team audit 50 of your active claims or past denials — completely free, with guaranteed under-48-hour findings.
Test our scrub rules and appeal workflow on 50 real claims. Zero commitment, no credit card required.
Upload your aging report for instant benchmark comparisons against MGMA standards and recoverable cash projections.